COMPANY
History
2020 ~
| 2022 | COVID-19 Antigen Diagnostic Kit FDA Approval (POC, OTC) | In Vitro Diagnostic Medical Device Clinically GMP Compliant | |||
| 2021 | Acquired of ISO 13485 | Patent Registered – Method for Amplification and Nucleic Acid Extraction for Detecting Foodborne Pathogenic Bacteria in Food | In vitro Diagnostic Medical Device GMP Certification (Clinical Chemistry Analyzer) | First Check (Pregnancy Test Kit) Item Approval (KFDA, No. 21-4671) | Assure 100 (COVID -19 Ag Detection kit) Export Approval (KFDA, No.21-771) |
| 2020 | Development of Anti-SARS-CoV-2 Nucleocapsid Protein | Development of Coronavirus (COVID-19) Nucleocapsid Protein | Patent Registered – Production Method of MERS Antigen Protein Using Drosophila Melanogaster S2 | Patent Registered – Hepatitis C Virus-Derived Fusion Protein and Diagnostic Kit Containing the Same |
2016 ~ 2019
| 2019 | Development of Canine CRP (Canine C-Reactive Protein) Antibodies | Acquired of Inno-Biz | Acquired of ISO 9001 | |
| 2018 | Company expansion (Current location) | Patent Registered – Immunoassay Method Utilizing Polystryptavidin | Development of NT-proBNP antibody | Development of Cardiac(Troponin I antibody) |
| 2017 | Development of Influenza A/B antibody | Development of Malaria PCR Kit | ||
| 2016 | Development of HCV & HIV Recombinant antigen | Development of Recombinant Antigens for Human Immunodeficiency Virus (HIV) | Patent Registered: Manufacturing Method of Semiconductor Fluorescent Nanoparticles for Optical and Display Applications. |
2002 ~ 2015
| 2015 | Certified as Venture Company | Acquired ISO 9001 Certification | Enrollment of Animal experiment facilities |
| 2014 | Established R&D Center | ||
| 2012 | Corporate Conversion – Bore Da Biotech Co., Ltd | ||
| 2002 | Established Bore Da Biotech |